BIOMAT Database Logo BIOMAT Database Logo

Molecular defect in factor IX Tokyo: substitution of valine-182 by alanine at position P2' in the second cleavage site by factor XIa resulting in impaired activation. 1993

H Maekawa, and T Sugo, and N Yamashita, and K Kamiya, and H Umeyama, and N Miura, and H Naka, and T Nishimura, and A Yoshioka, and M Matsuda
Institute of Hematology, Jichi Medical School, Tochigi, Japan.

Utilizing polymerase chain reaction and directly sequencing the amplified exon 6 of the factor IX gene derived from a mild hemophilia Bm patient, we have identified a T to C mutation at nucleotide 20,525. This point mutation predicted a Val182 to Ala substitution in the abnormal factor IX molecule, designated as factor IX Tokyo. The patient manifested a low factor IX activity and a moderately prolonged ox-brain prothrombin time but a normal factor IX antigen level in plasma. Immunopurified factor IX derived from the patient was found to have a normal molecular weight but a reduced specific activity (23% of normal). Limited proteolysis by activated factor XI or by a snake venom-derived factor X-activating enzyme was considerably delayed, indicating the presence of structural alteration(s) most probably at or near the second enzyme-cleavage site. Once activated, however, factor IXa Tokyo was able to activate factor X normally and was inactivated by antithrombin III also in a normal fashion. The structural model of factor IXa and a docking model of factor IX and activated factor VII (factor VIIa) suggested that the Val182 to Ala substitution would not affect the local conformation of the catalytic domain. This mutation would rather loosen the fitness of the molecule into the substrate-binding pocket of factor VIIa due to a shorter side chain of the Ala substitution at the P2' position of the second cleavage site.

UI MeSH Term Description Entries
D008297 Male Males
D008958 Models, Molecular Models used experimentally or theoretically to study molecular shape, electronic properties, or interactions; includes analogous molecules, computer-generated graphics, and mechanical structures. Molecular Models,Model, Molecular,Molecular Model
D008969 Molecular Sequence Data Descriptions of specific amino acid, carbohydrate, or nucleotide sequences which have appeared in the published literature and/or are deposited in and maintained by databanks such as GENBANK, European Molecular Biology Laboratory (EMBL), National Biomedical Research Foundation (NBRF), or other sequence repositories. Sequence Data, Molecular,Molecular Sequencing Data,Data, Molecular Sequence,Data, Molecular Sequencing,Sequencing Data, Molecular
D001777 Blood Coagulation The process of the interaction of BLOOD COAGULATION FACTORS that results in an insoluble FIBRIN clot. Blood Clotting,Coagulation, Blood,Blood Clottings,Clotting, Blood
D002836 Hemophilia B A deficiency of blood coagulation factor IX inherited as an X-linked disorder. (Also known as Christmas Disease, after the first patient studied in detail, not the holy day.) Historical and clinical features resemble those in classic hemophilia (HEMOPHILIA A), but patients present with fewer symptoms. Severity of bleeding is usually similar in members of a single family. Many patients are asymptomatic until the hemostatic system is stressed by surgery or trauma. Treatment is similar to that for hemophilia A. (From Cecil Textbook of Medicine, 19th ed, p1008) Christmas Disease,Factor IX Deficiency,Deficiency, Factor IX,F9 Deficiency,Haemophilia B,Hemophilia B Leyden,Hemophilia B(M),Plasma Thromboplastin Component Deficiency,Bs, Hemophilia,Deficiencies, F9,Deficiencies, Factor IX,Deficiency, F9,Disease, Christmas,F9 Deficiencies,Factor IX Deficiencies,Haemophilia Bs,Hemophilia Bs,Hemophilia Bs (M)
D003198 Computer Simulation Computer-based representation of physical systems and phenomena such as chemical processes. Computational Modeling,Computational Modelling,Computer Models,In silico Modeling,In silico Models,In silico Simulation,Models, Computer,Computerized Models,Computer Model,Computer Simulations,Computerized Model,In silico Model,Model, Computer,Model, Computerized,Model, In silico,Modeling, Computational,Modeling, In silico,Modelling, Computational,Simulation, Computer,Simulation, In silico,Simulations, Computer
D005164 Factor IX Storage-stable blood coagulation factor acting in the intrinsic pathway of blood coagulation. Its activated form, IXa, forms a complex with factor VIII and calcium on platelet factor 3 to activate factor X to Xa. Deficiency of factor IX results in HEMOPHILIA B (Christmas Disease). Autoprothrombin II,Christmas Factor,Coagulation Factor IX,Plasma Thromboplastin Component,Blood Coagulation Factor IX,Factor 9,Factor IX Complex,Factor IX Fraction,Factor Nine,Factor IX, Coagulation
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000293 Adolescent A person 13 to 18 years of age. Adolescence,Youth,Adolescents,Adolescents, Female,Adolescents, Male,Teenagers,Teens,Adolescent, Female,Adolescent, Male,Female Adolescent,Female Adolescents,Male Adolescent,Male Adolescents,Teen,Teenager,Youths
D000409 Alanine A non-essential amino acid that occurs in high levels in its free state in plasma. It is produced from pyruvate by transamination. It is involved in sugar and acid metabolism, increases IMMUNITY, and provides energy for muscle tissue, BRAIN, and the CENTRAL NERVOUS SYSTEM. Abufène,Alanine, L-Isomer,L-Alanine,Alanine, L Isomer,L Alanine,L-Isomer Alanine

Related Publications

H Maekawa, and T Sugo, and N Yamashita, and K Kamiya, and H Umeyama, and N Miura, and H Naka, and T Nishimura, and A Yoshioka, and M Matsuda
Blood clotting factor IX Kashihara: amino acid substitution of valine-182 by phenylalanine.
May 1989, Journal of biochemistry,
H Maekawa, and T Sugo, and N Yamashita, and K Kamiya, and H Umeyama, and N Miura, and H Naka, and T Nishimura, and A Yoshioka, and M Matsuda
Activation of factor IX by factor XIa.
July 2000, Trends in cardiovascular medicine,
H Maekawa, and T Sugo, and N Yamashita, and K Kamiya, and H Umeyama, and N Miura, and H Naka, and T Nishimura, and A Yoshioka, and M Matsuda
Blood clotting factor IX Niigata: substitution of alanine-390 by valine in the catalytic domain.
December 1988, Journal of biochemistry,
H Maekawa, and T Sugo, and N Yamashita, and K Kamiya, and H Umeyama, and N Miura, and H Naka, and T Nishimura, and A Yoshioka, and M Matsuda
Characterization of the defect in activation of factor IX Chapel Hill by human factor XIa.
December 1981, The Journal of clinical investigation,
H Maekawa, and T Sugo, and N Yamashita, and K Kamiya, and H Umeyama, and N Miura, and H Naka, and T Nishimura, and A Yoshioka, and M Matsuda
The factor IX phospholipid-binding site is required for calcium-dependent activation of factor IX by factor XIa.
June 1987, The Journal of biological chemistry,
H Maekawa, and T Sugo, and N Yamashita, and K Kamiya, and H Umeyama, and N Miura, and H Naka, and T Nishimura, and A Yoshioka, and M Matsuda
A mutation adjacent to the beta cleavage site of factor IX (valine 182 to leucine) results in mild haemophilia Bm.
June 1990, British journal of haematology,
H Maekawa, and T Sugo, and N Yamashita, and K Kamiya, and H Umeyama, and N Miura, and H Naka, and T Nishimura, and A Yoshioka, and M Matsuda
Identification of the molecular defect in factor IX Chapel Hill: substitution of histidine for arginine at position 145.
July 1983, Proceedings of the National Academy of Sciences of the United States of America,
H Maekawa, and T Sugo, and N Yamashita, and K Kamiya, and H Umeyama, and N Miura, and H Naka, and T Nishimura, and A Yoshioka, and M Matsuda
The mechanism underlying activation of factor IX by factor XIa.
May 2014, Thrombosis research,
H Maekawa, and T Sugo, and N Yamashita, and K Kamiya, and H Umeyama, and N Miura, and H Naka, and T Nishimura, and A Yoshioka, and M Matsuda
Factor XIa dimer in the activation of factor IX.
August 2005, Biochemistry,
H Maekawa, and T Sugo, and N Yamashita, and K Kamiya, and H Umeyama, and N Miura, and H Naka, and T Nishimura, and A Yoshioka, and M Matsuda
Phospholipids accelerate factor IX activation by surface bound factor XIa.
February 1984, British journal of haematology,
Copied contents to your clipboard!